Healthy Hair, Skin & Nails Blend
Published research and evidence base
Biotin (vitamin B7) is an essential cofactor for five carboxylases, and frank biotin deficiency causes alopecia and dermatitis that resolve with repletion. In people without a deficiency, however, the evidence that supplemental biotin improves hair, skin or nail outcomes is weak: systematic and narrative reviews consistently find only a handful of small, biased or negative studies. High-dose biotin is also a recognised cause of clinically significant interference in streptavidin-biotin immunoassays, producing falsely raised or lowered results for thyroid, cardiac, hormone and other analytes. Other B vitamins have their own dermatological evidence base, with nicotinamide the best studied, showing benefit for keratinocyte-cancer chemoprevention in immunocompetent high-risk patients but no benefit in organ-transplant recipients.
- Studies cited
- 15
- Published 2023+
- 12
- Newest paper
- 2026
- Last reviewed
- Aug 2026
Recurring themes in the literature
- biotin deficiency versus supplementation in replete individuals
- biotin-streptavidin immunoassay interference
- keratin and carboxylase biochemistry
- telogen effluvium and androgenetic alopecia adjuncts
- nutraceutical supplement trial quality
- nicotinamide and keratinocyte cancer chemoprevention
- brittle nail syndrome
15 published studies.
Ordered by strength of study design, then by recency. Every entry links to its source record so the finding can be checked against the paper rather than taken on our word.
- 01Systematic review2023
Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review.
Drake L, et al. · JAMA Dermatology · systematic review of MEDLINE, Embase and CINAHL from inception to 20 October 2021, restricted to individuals with hair loss and no known baseline nutritional deficiency; quality graded by Oxford CEBM criteria
The review found that the safety and effectiveness of nutritional supplements and dietary interventions for hair loss remain unclear in people without a documented baseline deficiency. It is the most widely cited systematic appraisal of the supplement category in dermatology.
- 02Human clinical2025
The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.
Patel MN, et al. · Cureus · randomised, double-blind, placebo-controlled trial, 105 enrolled and 97 completing, three arms (placebo; 1.25 mg plant-derived biotin; 1.25 mg biotin plus 21.75 mg silica), 90 days
Participants received placebo or one of two botanical biotin preparations for 90 days with clinical and instrumental assessment of hair, skin and nail parameters. The dose tested (1.25 mg) is far below the 5-10 mg commonly sold, and the study evaluated proprietary botanical extracts rather than synthetic biotin alone.
- 03Human clinical2025
The Clinical Evaluation of Serum WS Biotin, a Novel Encapsulated Form of D-Biotin With Improved Water Solubility, for Anti-Hair Shedding Applications. A Prospective Single-Arm, Nonrandomized, Pretest-Posttest Study.
Gonzalez Fernandez D, et al. · Health Science Reports · prospective single-arm, non-randomised, pretest-posttest study, n=22 volunteers with moderate to excessive hair shedding, topical application daily for 3 months
The authors stated explicitly that biotin has long been used as an oral supplement to promote hair growth and strength without solid evidence supporting the practice. Their own study was uncontrolled, topical rather than oral, and used modified pull test, modified hair wash test and phototrichogrammetry endpoints.
- 04Human clinical2024
Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial.
Valentim FO, et al. · Anais Brasileiros de Dermatologia · randomised crossover clinical trial in men comparing 5% topical minoxidil, 5 mg oral biotin, and the two combined
This randomised crossover trial directly compared oral biotin against an established topical hair-growth agent. The indexed record is a research letter with no abstract in PubMed or Europe PMC, so effect estimates were not extractable from the bibliographic record and the full text would need to be consulted before quoting a result.
- 05Human clinical2023
Impact of Biotin Supplementation on Human Chorionic Gonadotropin Immunoassays Utilizing Biotin-Streptavidin Binding Methods in Urine.
Goodrum JM, et al. · Clinical Chemistry · study of biotin supplementation effects on urinary hCG immunoassays that use biotin-streptavidin binding
Biotin supplementation was shown to affect hCG immunoassays that rely on biotin-streptavidin capture in urine, extending the interference problem beyond serum-based endocrine testing.
Reported safety finding. Biotin supplementation can distort urinary hCG immunoassay results.
- 06Human clinical2023
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Allen NC, et al. · The New England Journal of Medicine · phase 3 randomised trial, organ-transplant recipients with at least two keratinocyte cancers in the past 5 years, nicotinamide 500 mg or placebo twice daily for 12 months, dermatologist examination every 3 months
This phase 3 trial tested whether the benefit seen in immunocompetent patients extended to immunosuppressed transplant recipients. It is the key negative counterweight to enthusiasm for B-vitamin chemoprevention and shows that benefit in one population does not generalise.
- 07Human clinical2017
Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.
Li D, et al. · JAMA · prospective study of biotin ingestion in healthy adults with paired hormone and non-hormone assay measurement
This is the landmark human demonstration that ingesting biotin at supplement doses alters the measured performance of hormone and non-hormone immunoassays in otherwise healthy people. It converted a laboratory curiosity into a recognised clinical safety issue.
Reported safety finding. Directly demonstrated assay distortion in healthy adults after biotin ingestion.
- 08Human clinical2015
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Chen AC, et al. · The New England Journal of Medicine · phase 3 double-blind randomised controlled trial, n=386 participants with at least two non-melanoma skin cancers in the previous 5 years, nicotinamide 500 mg twice daily or placebo for 12 months, 18-month follow-up
The trial evaluated the number of new basal-cell and squamous-cell carcinomas over a 12-month intervention period in high-risk immunocompetent participants. It remains the landmark demonstration that a B vitamin can alter a hard dermatological endpoint at pharmacological dose in a selected population.
- 09In vitro2026
In-vitro verification of tolerance limits for biotin interference of routine biochemistry and immunology assays.
Swallow K, et al. · Annals of Clinical Biochemistry · samples spiked to serum concentrations equivalent to 0.05-3600 mg/day exogenous biotin, tested across all relevant laboratory assays
Biotin interference was assessed against allowable measurement uncertainty across the full routine biochemistry and immunology repertoire, and the authors noted that not all manufacturers have issued warnings or reassurances about their assays. Interference can raise or lower a result depending on assay format.
Reported safety finding. Exogenous biotin at supplement-level doses can bias routine laboratory results in either direction, and manufacturer warnings are inconsistent.
- 10Review2026
Biotin Supplements for Hair and Nail Regrowth: A Caution for Oncologists.
Mager L, et al. · JCO Oncology Practice · clinical commentary directed at oncologists whose patients take biotin for post-chemotherapy hair and nail regrowth
The article cautions oncologists about biotin supplements taken for hair and nail regrowth, a population in whom assay interference has direct consequences for tumour-marker and hormone monitoring. The PubMed record carries no abstract.
Reported safety finding. Biotin supplementation flagged as a hazard in oncology practice.
- 11Review2026
Adjunctive approaches for androgenetic alopecia: A clinical review of nutritional, light-based, topical, and lifestyle interventions.
Podolsky AS, et al. · Journal of the American Academy of Dermatology · clinical review appraising nutritional supplements and nutraceuticals, light-based therapies, topicals and lifestyle interventions for androgenetic alopecia
Among reviewed adjunctive interventions some demonstrated modest benefit while many lacked adequate data, with persisting gaps including small sample sizes, heterogeneous methods and limited long-term follow-up.
- 12Review2025
Biotin Supplementation-The Cause of Hypersensitivity and Significant Interference in Allergy Diagnostics.
Lis K, et al. · Nutrients · review of biotin exposure via supplements, cosmetics and medicines in relation to hypersensitivity and allergy testing
The authors found little evidence that oral or topical biotin is a significant sensitising agent and characterised true biotin allergy as very rare, while identifying biotin as a significant source of interference in allergy diagnostic assays.
Reported safety finding. Biotin interferes with allergy diagnostic immunoassays; direct sensitisation appears rare.
- 13Review2024
Biotin for Hair Loss: Teasing Out the Evidence.
Yelich A, et al. · The Journal of Clinical and Aesthetic Dermatology · PubMed literature review of oral biotin for hair growth or quality, excluding case reports and case series; three studies met inclusion criteria
The single highest-quality included study was double-blind and placebo-controlled and found no difference between biotin and placebo for hair growth. The other two studied specific populations (isotretinoin-treated patients and post-sleeve-gastrectomy women), were susceptible to multiple biases, and had no striking results favouring biotin.
- 14Review2017
A Review of the Use of Biotin for Hair Loss.
Patel DP, Swink SM, Castelo-Soccio L · Skin Appendage Disorders · review of published reports of biotin use for hair and nail disorders
This is the reference review establishing that reported clinical benefit from biotin is confined to patients with an underlying biotin deficiency or a specific inherited or acquired cause, and that evidence for supplementation in otherwise healthy individuals is lacking.
- 15Case report2025
High-Dose Biotin Supplementation Exacerbates Chronic Migraine: A Case Report.
Sanosi AA, et al. · International Medical Case Reports Journal · single patient with 20-year history of controlled classic migraine
A patient developed daily severe headaches unresponsive to triptans after starting biotin 10,000 mcg daily, with multiple emergency visits and significant quality-of-life impact. The proposed mechanism was alteration of mitochondrial energy metabolism affecting neurotransmitter synthesis.
Reported safety finding. Chronic migraine exacerbation temporally associated with high-dose (10 mg) biotin supplementation.
What this evidence does not establish.
No adequately powered randomised placebo-controlled trial has shown that biotin supplementation improves hair, skin or nail outcomes in people with normal biotin status; the only high-quality placebo-controlled study identified in a 2024 review found no difference from placebo. Doses commonly sold (5-10 mg, roughly 150-300 times the adequate intake) have no established efficacy threshold and are well within the range that distorts streptavidin-biotin immunoassays. The multi-ingredient 'hair, skin and nails' complex format has not been tested as a formulation against placebo for any hard endpoint, and benefits shown for one B vitamin at pharmacological dose in a selected population (nicotinamide in high-risk immunocompetent patients) do not generalise, as the negative transplant-recipient trial demonstrates.
Common questions about the research.
- Why B vitamins for hair, skin, and nail research?
Several B vitamins are cofactors in keratinocyte metabolism — biotin for carboxylase enzymes, pantothenic acid as the coenzyme A precursor, niacinamide as the NAD precursor. The review literature links deficiencies of these micronutrients to disordered hair and nail growth, which is the research context for the formulation.
- Is there strong evidence for supplementation without a deficiency?
The published reviews are candid on this point: documented improvement is concentrated in cases with an underlying deficiency or pathology, and evidence for benefit in replete subjects is limited. The cited literature is the best guide to where the evidence is solid and where it thins out.
- What does the research on biotin supplementation show?
Frank biotin deficiency causes alopecia and dermatitis that resolve with repletion, but the evidence for supplementation in people with normal biotin status is weak. A 2024 review of oral biotin for hair growth or quality found only three eligible studies, and the single highest-quality one, which was double-blind and placebo-controlled, found no difference between biotin and placebo. A 2023 systematic review restricted to individuals with hair loss and no known baseline nutritional deficiency concluded that the safety and effectiveness of nutritional supplements for that group remain unclear.
- Does high-dose biotin interfere with laboratory tests?
Yes, and this is a documented rather than theoretical problem. A 2017 prospective study in healthy adults demonstrated that ingesting biotin at supplement doses altered measured results across paired hormone and non-hormone immunoassays that rely on streptavidin-biotin capture. Later work extended the finding to urinary hCG immunoassays, and a 2026 assessment spanning the routine biochemistry and immunology repertoire found bias in either direction, with the authors noting that not all manufacturers have issued warnings.
Available from our catalog
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no study summarised here should be read as a recommendation.